Progressive research of Alzheimer's disease-related blood markers

doi:10.3969/j.issn.1673-8640.2020.04.019

Abstract

Abstract:

Alzheimer's disease（AD）is a degenerative disease of the central nervous system with clinical manifestations of memory impairment,cognitive impairment,later personality and behavioral changes. Recently,studies have shown that many blood markers are closely related to AD,like protein,gene mutation,microRNA（miRNA）,which may play a certain role in predicting the risk of AD,reflecting the stage of AD and supporting the diagnosis of AD. In addition,the determination method of blood markers is simple and easy,therefore screening ideal AD-related blood markers is beneficial to the screening and treatment of AD. In this review,the latest research status of AD-related blood markers is summarized,and the possibility and limitation of its clinical application are discussed.

Key words: Blood marker, Alzheimer's disease, Screening, Diagnosis

CLC Number:

R446.1

CHEN Xiaotong, LIN Yong. Progressive research of Alzheimer's disease-related blood markers[J]. Laboratory Medicine, 2020, 35(4): 374-379.

References 50.

1.	SUGINO H,WATANABE A,AMADA N,et al.Global trends in alzheimer disease clinical development:increasing the probability of success[J]. Clin Ther,2015,37(8):1632-1642.
2.	FRICKER M,TOLKOVSKY A M,BORUTAITE V,et al.Neuronal cell death[J]. Physiol Rev,2018,98(2):813-880.
3.	DUBOIS B,FELDMAN H H,JACOVA C,et al.Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria[J]. Lancet Neurol,2007,6(8):734-746.
4.	DUBOIS B,FELDMAN H H,JACOVA C,et al.Advancing research diagnostic criteria for Alzheimer's disease:the IWG-2 criteria[J]. Lancet Neurol,2014,13(6):614-629.
5.	JACK C R Jr,BENNETT D A,BLENNOW K,et al. NIA-AA research framework:toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement,2018,14(4):535-562.
6.	JAGUST W.Imaging the evolution and pathophysiology of Alzheimer disease[J]. Nat Rev Neurosci,2018,19(11):687-700.
7.	SCHELTENS P,BLENNOW K,BRETELER M M,et al.Alzheimer's disease[J]. Lancet,2016,388(10043):505-517.
8.	WANG J,GU B J,MASTERS C L,et al.A systemic view of Alzheimer disease-insights from amyloid-β metabolism beyond the brain[J]. Nat Rev Neurol,2017,13(10):612-623.
9.	VERBERK I M W,SLOT R E,VERFAILLIE S C J,et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes[J]. Ann Neurol,2018,84(5):648-658.
10.	NAKAMURA A,KANEKO N,VILLEMAGNE V L,et al.High performance plasma amyloid-β biomarkers for Alzheimer's disease[J]. Nature,2018,554(7691):249-254.
11.	NABERS A,PERNA L,LANGE J,et al.Amyloid blood biomarker detects Alzheimer's disease[J]. EMBO Mol Med,2018,10(5).
12.	VARMA V R,OOMMEN A M,VARMA S,et al.Brain and blood metabolite signatures of pathology and progression in Alzheimer disease:a targeted metabolomics study[J]. PLoS Med,2018,15(1):e1002482.
13.	SHEN Y,WANG H,SUN Q,et al.Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment[J]. Biol Psych,2018,83(5):447-455.
14.	PEÑA-BAUTISTA C,VIGOR C,GALANO J M,et al. Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer disease detection[J]. Free Radic Biol Med,2018,124:388-394.
15.	TROUGAKOS I P.The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress:implications in therapeutic approaches-a mini-review[J]. Gerontology,2013,59(6):514-523.
16.	PERROTTE M,LE PAGE A,FOURNET M,et al.Blood-based redox-signature and their association to the cognitive scores in MCI and Alzheimer's disease patients[J]. Free Radic Biol Med,2019,130:499-511.
17.	PADURARIU M,CIOBICA A,HRITCU L,et al.Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease[J]. Neurosci Lett,2010,469(1):6-10.
18.	HEPPNER F L,RANSOHOFF R M,BECHER B.Immune attack:the role of inflammation in Alzheimer disease[J]. Nat Rev Neurosci,2015,16(6):358-372.
19.	HENEKA M T,GOLENBOCK D T,LATZ E.Innate immunity in Alzheimer's disease[J]. Nat Immunol,2015,16(3):229-236.
20.	FORLENZA O V,DINIZ B S,TALIB L L,et al.Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment[J]. Dement Geriatr Cogn Disord,2009,28(6):507-512.
21.	HARDY J,SELKOE D J.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics[J]. Science,2002,297(5580):353-356.
22.	HEILIG E A,XIA W,SHEN J,et al.A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity[J]. J Biol Chem,2010,285(29):22350-22359.
23.	VEUGELEN S,SAITO T,SAIDO T C,et al.Familial Alzheimer's disease mutations in presenilin generate amyloidogenic Aβ peptide seeds[J]. Neuron,2016,90(2):410-416.
24.	WANG Y,MANDELKOW E.Tau in physiology and pathology[J]. Nat Rev Neurosci,2016,17(1):5-21.
25.	MIELKE M M,HAGEN C E,XU J,et al.Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography[J]. Alzheimers Dement,2018,14(8):989-997.
26.	OLSSON B,LAUTNER R,ANDREASSON U,et al.CSF and blood biomarkers for the diagnosis of Alzheimer's disease:a systematic review and meta-analysis[J]. Lancet Neurol,2016,15(7):673-684.
27.	CORSI M M,LICASTRO F,PORCELLINI E,et al.Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease:relationship with neuro-degeneration[J]. Biogerontology,2011,12(5):451-454.
28.	丁冰玉,林萍,李擎天. 植物血凝素刺激外周血单个核细胞Th1/Th2细胞因子分泌对阿尔茨海默病的诊断价值[J]. 检验医学,2018,33(4):290-294.
29.	D'ANNA L,ABU-RUMEILEH S,FABRIS M,et al. Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients[J]. Neurodegener Dis,2017,17(4-5):227-234.
30.	TOGO T,AKIYAMA H,KONDO H,et al.Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases[J]. Brain Res,2000,885(1):117-121.
31.	MOCALI A,CEDROLA S,DELLA MALVA N,et al.Increased plasma levels of soluble CD40,together with the decrease of TGF beta 1,as possible differential markers of Alzheimer disease[J]. Exp Gerontol,2004,39(10):1555-1561.
32.	BROSSERON F,KRAUTHAUSEN M,KUMMER M,et al.Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease:a comparative overview[J]. Mol Neurobiol,2014,50(2):534-544.
33.	TRAMUTOLA A,ABATE G,LANZILLOTTA C,et al.Protein nitration profile of CD3+:lymphocytes from Alzheimer disease patients:novel hints on immunosenescence and biomarker detection[J]. Free Radic Biol Med,2018,129:430-439.
34.	BHATNAGAR S,CHERTKOW H,SCHIPPER H M,et al.Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma[J]. Front Mol Neurosci,2014,7:2.
35.	AYBEK H,ERCAN F,ASLAN D,et al.Determination of malondialdehyde,reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli,Turkey[J]. Clin Biochem,2007,40(3-4):172-176.
36.	FIANDACA M S,KAPOGIANNIS D,MAPSTONE M,et al.Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes:a case-control study[J]. Alzheimers Dement,2015,11(6):600-607.e1.
37.	HARA N,KIKUCHI M,MIYASHITA A,et al.Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease[J]. Acta Neuropathol Commun,2017,5(1):10.
38.	YANG T T,LIU C G,GAO S C,et al.The serum exosome derived microRNA-135a,-193b,and -384 were potential Alzheimer's disease biomarkers[J]. Biomed Environ Sci,2018,31(2):87-96.
39.	HONG S,BEJA-GLASSER V FNFONOYIM B M,et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science,2016,352(6286):712-716.
40.	ZHOU X,CHEN Y,MOK K Y,et al.Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer's disease pathogenesis[J]. Proc Natl Acad Sci U S A,2018,115(8):1697-1706.
41.	WENDELN A C,DEGENHARDT K,KAURANI L,et al.Innate immune memory in the brain shapes neurological disease hallmarks[J]. Nature,2018,556(7701):332-338.
42.	SNYDER H M,CARRILLO M C,GRODSTEIN F,et al.Developing novel blood-based biomarkers for Alzheimer's disease[J]. Alzheimers Dement,2014,10(1):109-114.
43.	FIORINI M,BONGIANNI M,BENEDETTI M D,et al.Reappraisal of Aβ40 and Aβ42 peptides measurements in cerebrospinal fluid of patients with Alzheimer's disease[J]. J Alzheimers Dis,2018,66(1):219-227.
44.	SWEENEY M D,SAGARE A P,ZLOKOVIC B V.Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol,2018,14(3):133-150.
45.	HENRIKSEN K,O'BRYANT S E,HAMPEL H,et al. The future of blood-based biomarkers for Alzheimer's disease[J]. Alzheimers Dement,2014,10(1):115-131.
46.	THAMBISETTY M,LOVESTONE S.Blood-based biomarkers of Alzheimer's disease:challenging but feasible[J]. Biomark Med,2010,4(1):65-79.
47.	O'BRYANT S E,EDWARDS M,JOHNSON L,et al. A blood screening test for Alzheimer's disease[J]. Alzheimer's Dementia(Amst),2016,3:83-90.
48.	WOOD H.Alzheimer disease:localized proteomics distinguishes AD subtypes[J]. Nat Rev Neurol,2017,13(5):260.
49.	ROSENBERG R N,LAMBRACHT-WASHINGTON D,YU G,et al.Genomics of Alzheimer disease:a review[J]. JAMA Neurol,2016,73(7):867-874.
50.	XIANG Y,LAM S M,SHUI G.What can lipidomics tell us about the pathogenesis of Alzheimer disease?[J]. Biol Chem,2015,396(12):1281-1291.

[1]	Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine Shanghai Center for Clinical Laboratory, Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine Clinical Laboratory Society of Chinese Association of Integrative Medicine, Tumor Immunology Branch of Shanghai Society for Immunology Molecular Diagnostics Society of Shanghai Medical Association. Expert consensus on non-invasive laboratory diagnosis for hepatic fibrosis [J]. Laboratory Medicine, 2025, 40(7): 625-641.
[2]	XIA Yuanzhi, YIN Xiangfei, LIN Sien, LIANG Xiaoliang. Prenatal diagnosis value of BoBs technique assay for chromosomal aneuploidy abnormality：a meta analysis [J]. Laboratory Medicine, 2025, 40(5): 477-483.
[3]	ZHANG Guoying, LU Zhongkui, WANG Yuling, XIA Xia, MENG Ke, HE Fang, HUANG Zihui, YANG Zengmin, LIU Xin. Application of gamma-interferon inducible protein-10 mRNA determination technology in diagnosis of extrapulmonary tuberculosis [J]. Laboratory Medicine, 2025, 40(4): 372-376.
[4]	WENG Wenhao. Research progress in laboratory diagnosis and immune regulatory mechanisms of pediatric autoimmune diseases [J]. Laboratory Medicine, 2025, 40(3): 205-208.
[5]	MA Zhan, WENG Wenhao. Autoimmune liver disease in children and progress of laboratory diagnosis [J]. Laboratory Medicine, 2025, 40(3): 218-222.
[6]	YU Jiajie, ZHANG Zhizhi, LUO Qingqiong, KE Xing. Predicting early colorectal tumor risk using a deep learning model based on multiple serum tumor markers [J]. Laboratory Medicine, 2025, 40(3): 253-258.
[7]	WANG Binbin, LI Fengqi, GUO Fenglian, ZHANG Rui, KANG Huihui, WANG Yuetong. Clinical characteristic and genetic analysis of a new mutation of SF3B4 gene causing neonatal acrofacial dysostosis 1，Nager type [J]. Laboratory Medicine, 2025, 40(2): 142-147.
[8]	WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing. Changes and clinical value of blood coagulation indexes in children with infection [J]. Laboratory Medicine, 2025, 40(2): 178-181.
[9]	SHI Jian, LEI Jing, GENG Yan. Application role of metagenomic next-generation sequencing in diagnosis of pulmonary infections [J]. Laboratory Medicine, 2025, 40(12): 1232-1236.
[10]	XU Ben, FENG Zhangliang, SONG Xiaojun, JIN Dazhi, CHEN Yu. Research progress in molecular diagnostic techniques for respiratory tract infections [J]. Laboratory Medicine, 2025, 40(10): 1019-1024.
[11]	LUO Jing, YUAN Jiayi, YAO Xiaoyan, FAN Lieying. Changes in cathepsin C expression in peripheral blood monocyte subsets of RA patients [J]. Laboratory Medicine, 2025, 40(10): 933-940.
[12]	DING Jing, LI Huidan, ZHANG Chunling, WANG Xiaorui, LIU Weiling, LIN Lihui, QIU Huiying. Analysis of laboratory diagnosis and prognostic factors of myeloid neoplasms based on different classification criteria [J]. Laboratory Medicine, 2025, 40(1): 25-31.
[13]	JIN Chunlei, HU Hui, LIU Jiao, YANG Mufeng, SHAN Qunda, CHEN Penglong. Application role of single nucleotide polymorphism microarray analysis in pregnant women with different prenatal diagnostic indications [J]. Laboratory Medicine, 2024, 39(9): 841-846.
[14]	DING Jing, ZHANG Chunling, WANG Xiaorui, LI Huidan, WANG Hongling, LIU Weiling, LIN Lihui, LI Li. Laboratory diagnosis and prognostic factor analysis of core binding factor-related acute myeloid leukemia [J]. Laboratory Medicine, 2024, 39(7): 673-681.
[15]	WANG Tiankai, LIU Lin, JIN Peipei, WANG Fang, DING Ning. Clinical value of new neutrophil parameter NEU-X，NEU-Y and NEU-Z in diagnosis of sepsis [J]. Laboratory Medicine, 2024, 39(7): 682-686.